ARES — Ares Management Corporation

The analyst consensus is Buy (17 Buy/Strong Buy, 5 Hold) and the Q2 2026 revenue beat supports a constructive tone. However, the stock is down 12-14% year-to-date, is only about 5% below the FMP consensus price target of $149.33, and reported revenue growth decelerated sharply in the latest quarter, so near-term sentiment is balanced rather than bullish.

Reported revenue grew strongly through 2024-25, from $671M in Sep-2023 to a peak of $1.77B in Dec-2025, but the last two reported quarters declined sequentially: $1.53B in Mar-2026 and $1.43B in Jun-2026. YoY growth slowed from +71% in Jun-2025 and +47% in Sep-2025 to just +5.8% in Jun-2026. Operating margins are also volatile: 29.3% in Dec-2025, then 23.8% and 17.4% in the two 2026 quarters. The underlying data also flags a possible non-organic distortion around Sep-2024 to Dec-2024, so trend comparisons around that point are unreliable. This is not a stable linear growth story; it is a high-quality franchise with choppy, currently decelerating reported GAAP metrics.

As of 2026-08-27, ARES looks expensive on trailing metrics: TTM P/E is 62.2x, price/sales is 7.3x versus a 5-year average of 5.5x, and price/book is 8.1x. On consensus forward EPS of $5.87, the forward P/E is about 24.3x, which is more reasonable but still not cheap. The PEG ratio of 2.17 indicates the market is already paying up for growth, and the 3.66% dividend yield provides only modest downside cushion.

The stock is not pricing in a broken business; it is pricing in delivery of roughly $5.87 of forward EPS and continued strong fundraising. If the back-half transaction pipeline materializes and fee-related earnings keep growing, the current forward multiple can hold. If G&A pressure continues, realizations disappoint, or revenue growth stays in single digits, forward estimates are at risk and the multiple could compress. The market has already given ARES credit for its franchise, so the easy part of that trade is done.

As of 2026-08-27, RSI is 58.37, the price is 1.2% above the 20-day SMA, 10.6% above the 50-day SMA, and 6.7% above the 200-day SMA. That is a short-term uptrend/rebound, not an oversold setup, and the stock remains 24% below its 52-week high. For a new position, a better entry would likely be a pullback toward the 50-day SMA or an RSI reset below 40; chasing here offers limited technical edge.

• Structural private-credit tailwind as banks retreat from direct lending, benefiting Ares' credit and asset-based finance strategies.
• Interest-rate path: floating-rate credit assets protect deployment yields, but rate shifts drive mark-to-market and transaction volumes.
• M&A and corporate transaction environment: deal activity determines deployment, capital markets fees, and performance-fee realizations.
• Continuing institutional allocations to private markets, which support fundraising but can be uneven quarter to quarter.
• Potential regulatory scrutiny of private credit and asset-based finance as these markets grow.

• Q3 2026 earnings in late October/early November 2026; management's guided back-half pipeline pickup could show re-accelerating revenue and realizations.
• Further record fundraising and scaling of newer strategies such as infrastructure debt and asset-based finance.
• A pickup in M&A and transaction activity, which would drive carried interest and after-tax realized income.
• Positive analyst price-target revisions or momentum flows if growth reaccelerates.

• Revenue deceleration: Q2 2026 YoY revenue growth was only about 5.8%, down sharply from the 40-70% range of prior quarters.
• GAAP earnings and FCF volatility: operating cash flow was negative in the Dec-2025 and Jun-2026 quarters, and GAAP net income in Dec-2025 was only $54M on $1.77B of revenue.
• High balance-sheet leverage: long-term debt was $14.06B versus $3.97B of stockholders' equity as of Jun-2026, leaving limited cushion if marks or credit losses bite.
• Valuation mean-reversion risk: price/sales of 7.3x versus the 5-year average of 5.5x leaves little margin of safety if growth disappoints.
• G&A/margin compression from investments in technology, distribution, and meetings, which could keep operating margins under pressure.

ARES is a high-quality alternative asset manager with a durable private-credit franchise and record fundraising, but at $142.41 the stock is paying a full price for a business whose reported fundamentals look weak and whose latest-quarter revenue growth is decelerating. Risk/reward is unattractive here: I would not initiate or add at this level, and I would wait for a lower entry or evidence of re-accelerating growth and cleaner cash-flow generation.

Applied a 24x multiple to next-FY consensus EPS of $5.87, approximately the stock's current forward multiple, because I would not grant a premium until revenue reaccelerates and cash-flow quality improves. 24 × $5.866 = $140.78.